Clovis Jumps as Cancer Drug Gets Priority for FDA Review

(Bloomberg) -- Clovis Oncology Inc. shares soared after the U.S. Food and Drug Administration granted a faster review process to the company’s experimental ovarian cancer drug rucaparib.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.